<DOC>
	<DOCNO>NCT01405833</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability , pharmacokinetic ( PK ) profile 3 intravenous ( IV ) injection BG00010 give 2 fixed schedule ; weekly frequently every 48 hour ( 3 time per week ) . Secondary objective study study population explore repeated-dose immunogenicity BG00010 explore potential BG00010 reduce pain follow multiple-dose administration .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Safety BG00010 ( Neublastin ) Subjects With Sciatica .</brief_title>
	<detailed_description />
	<mesh_term>Sciatica</mesh_term>
	<criteria>Key Must diagnosis unilateral sciatica , determine Investigator outline protocol . Sciatica symptom must present 3 month prior Screening Visit . Must rate pain &gt; /=40 mm 100 mm Visual Analog Scale ( VAS ) ShortForm McGill Pain Questionnaire ( SFMPQ ) Screening Baseline Visits . Key History malignancy clinically relevant allergy and/or cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic ( related sciatica ) , dermatologic , rheumatic/joint , psychiatric , renal , and/or major disease . History severe pain judge Investigator , cause sciatica 3 month prior Screening Visit . Signs symptoms peripheral neuropathy , symptom sciatica 3 month prior Screening Visit . Current generalize myalgia Serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . History positive screen test hepatitis C infection , hepatitis B infection and/or positive hepatitis B core antibody positive human immunodeficiency virus ( HIV ) antibody . Subjects HBsAg negative HBcAb positive allow participate positive HBsAb IgG ( see Centers Disease Control Prevention 's interpretation hepatitis B serology panel ) . Treatment prescription medication and/or thecounter product herbal supplement , unless dose stable 2 week prior Baseline Visit . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>